SOURCE: The Bedford Report

The Bedford Report

April 12, 2011 08:16 ET

Rich Pipelines Send Biotech Stocks Soaring

The Bedford Report Provides Analyst Research on Human Genome Sciences & Prana Biotech

NEW YORK, NY--(Marketwire - Apr 12, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Human Genome Sciences, Inc. (NASDAQ: HGSI) and Prana Biotechnology Limited (NASDAQ: PRAN). Access to the full company reports can be found at:

www.bedfordreport.com/2011-04-HGSI
www.bedfordreport.com/2011-04-PRAN

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Recently the FDA approved Human Genome Sciences' Lupus Drug, Benlysta. Prior to Benlysta, FDA last approved drugs to treat lupus, Plaquenil (hydroxychloroquine) and corticosteroids, in 1955. Aspirin was approved to treat lupus in 1948. Human Genome Sciences has rich pipeline, with two other major drugs in Phase III development: Darapladib, which treats cardiovascular disease, and Syncria, which treats Type II Diabetes.

Prana Biotechnology made significant headlines last month after it announced promising studies for its Alzheimer's treatment, PBT2. Prana said that it has published a study that showed PBT2 helped repair brain damage in mice stricken with Alzheimer's disease.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information